Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Antitumor effects of the GM3(Neu5Gc) ganglioside-specific humanized antibody 14F7hT against Cmah-transfected cancer cells.

Dorvignit D, Boligan KF, Relova-Hernández E, Clavell M, López A, Labrada M, Simon HU, López-Requena A, Mesa C, von Gunten S.

Sci Rep. 2019 Jul 9;9(1):9921. doi: 10.1038/s41598-019-46148-1.

2.

Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment.

Haas Q, Boligan KF, Jandus C, Schneider C, Simillion C, Stanczak MA, Haubitz M, Seyed Jafari SM, Zippelius A, Baerlocher GM, Läubli H, Hunger RE, Romero P, Simon HU, von Gunten S.

Cancer Immunol Res. 2019 May;7(5):707-718. doi: 10.1158/2326-6066.CIR-18-0505. Epub 2019 Apr 15.

PMID:
30988027
3.

Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo.

Basaco T, Pektor S, Bermudez JM, Meneses N, Heller M, Galván JA, Boligán KF, Schürch S, von Gunten S, Türler A, Miederer M.

Pharmaceuticals (Basel). 2018 Nov 28;11(4). pii: E132. doi: 10.3390/ph11040132.

4.

Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.

Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von Gunten S, Tzankov A, Tietze L, Lardinois D, Heinzelmann-Schwarz V, von Bergwelt-Baildon M, Zhang W, Lenz HJ, Han Y, Amos CI, Syedbasha M, Egli A, Stenner F, Speiser DE, Varki A, Zippelius A, Läubli H.

J Clin Invest. 2018 Nov 1;128(11):4912-4923. doi: 10.1172/JCI120612. Epub 2018 Sep 24.

5.

Innate lymphoid cells in asthma: cannabinoids on the balance.

Boligan KF, von Gunten S.

Allergy. 2017 Jun;72(6):839-841. doi: 10.1111/all.13145. No abstract available.

PMID:
28226397
6.

The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites.

Schneider C, Smith DF, Cummings RD, Boligan KF, Hamilton RG, Bochner BS, Miescher S, Simon HU, Pashov A, Vassilev T, von Gunten S.

Sci Transl Med. 2015 Jan 7;7(269):269ra1. doi: 10.1126/scitranslmed.3010524.

7.

Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.

Boligan KF, Mesa C, Fernandez LE, von Gunten S.

Cell Mol Life Sci. 2015 Apr;72(7):1231-48. doi: 10.1007/s00018-014-1799-5. Epub 2014 Dec 7. Review.

PMID:
25487607
8.

Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.

Jandus C, Boligan KF, Chijioke O, Liu H, Dahlhaus M, Démoulins T, Schneider C, Wehrli M, Hunger RE, Baerlocher GM, Simon HU, Romero P, Münz C, von Gunten S.

J Clin Invest. 2014 Apr;124(4):1810-20. doi: 10.1172/JCI65899. Epub 2014 Feb 24.

9.

Breast cancer suppressor candidate-1 (BCSC-1) is a melanoma tumor suppressor that down regulates MITF.

Anghel SI, Correa-Rocha R, Budinska E, Boligan KF, Abraham S, Colombetti S, Fontao L, Mariotti A, Rimoldi D, Ghanem GE, Fisher DE, Lévy F, Delorenzi M, Piguet V.

Pigment Cell Melanoma Res. 2012 Jul;25(4):482-7. doi: 10.1111/j.1755-148X.2012.01018.x. Erratum in: Pigment Cell Melanoma Res. 2012 Nov;25(6):834. Correa-Rochal, Rafael [corrected to Correa-Rocha, Rafael]; Boliganl, Kayluz F [corrected to Boligan, Kayluz F].

PMID:
22594792

Supplemental Content

Loading ...
Support Center